BRPI0415654A - composições farmacêuticas para uso terapêutico, uso do antìgeno de superfìcie do vìrus da hepatite b, e, método para o tratamento de infecções por vìrus de progressão crÈnica - Google Patents

composições farmacêuticas para uso terapêutico, uso do antìgeno de superfìcie do vìrus da hepatite b, e, método para o tratamento de infecções por vìrus de progressão crÈnica

Info

Publication number
BRPI0415654A
BRPI0415654A BRPI0415654-4A BRPI0415654A BRPI0415654A BR PI0415654 A BRPI0415654 A BR PI0415654A BR PI0415654 A BRPI0415654 A BR PI0415654A BR PI0415654 A BRPI0415654 A BR PI0415654A
Authority
BR
Brazil
Prior art keywords
hepatitis
pharmaceutical compositions
surface antigen
virus
treatment
Prior art date
Application number
BRPI0415654-4A
Other languages
English (en)
Inventor
Julio Cesar Aguilar Rubido
Enrique Iglesias Perez
Yadira Lobaina Mato
Daymir Garcia Gonzales
Verena Lucila Muzio Gonzalez
Gerardo Enrique Guillen Nieto
Nelson Acosta Rivero
Raimundo Ubieta Gomez
Julio Cesar Alvarez Obregon
Santiago Due As Carrera
Carlos Duarte Cano
Peter Vanlandshoot
Luis Saturnino Herrer Martinez
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of BRPI0415654A publication Critical patent/BRPI0415654A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"COMPOSIçõES FARMACêUTICAS PARA USO TERAPêUTICO, USO DO ANTìGENO DE SUPERFìCIE DO VìRUS DA HEPATITE B, E, MéTODO PARA O TRATAMENTO DE INFECçõES POR VìRUS DE PROGRESSãO CRÈNICA". Vacinas terapêuticas contra patógenos que causam doenças crónicas. O uso do antígeno da superfície do vírus da hepatite B (HBsAg), produzido por via recombinante a partir de Pichia pastoris, como componente principal, para a obtenção de composições farmacêuticas com fins terapêuticos. As mesmas podem compreender a combinação do antígeno de hepatite b com outros antígenos co-administrados. Estas formulações são capazes de gerar uma potente resposta linfoproliferativa e de linfócitos T citotóxicos, além de uma considerável resposta de anticorpos específicos, o que as torna muito efetivas para o tratamento destas doenças em humanos.
BRPI0415654-4A 2003-10-20 2004-10-20 composições farmacêuticas para uso terapêutico, uso do antìgeno de superfìcie do vìrus da hepatite b, e, método para o tratamento de infecções por vìrus de progressão crÈnica BRPI0415654A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20030240A CU23405A1 (es) 2003-10-20 2003-10-20 Composiciones farmacéuticas para uso terapéutico
PCT/CU2004/000011 WO2005037311A1 (es) 2003-10-20 2004-10-20 Composiciones farmacéuticas para uso terapéutico

Publications (1)

Publication Number Publication Date
BRPI0415654A true BRPI0415654A (pt) 2006-12-19

Family

ID=34441708

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415654-4A BRPI0415654A (pt) 2003-10-20 2004-10-20 composições farmacêuticas para uso terapêutico, uso do antìgeno de superfìcie do vìrus da hepatite b, e, método para o tratamento de infecções por vìrus de progressão crÈnica

Country Status (14)

Country Link
US (1) US20070275012A1 (pt)
EP (1) EP1676587A1 (pt)
JP (1) JP2007509081A (pt)
KR (1) KR20060117920A (pt)
CN (1) CN1882359A (pt)
AR (1) AR046063A1 (pt)
AU (1) AU2004281098B2 (pt)
BR (1) BRPI0415654A (pt)
CA (1) CA2542680A1 (pt)
CU (1) CU23405A1 (pt)
MX (1) MXPA06004387A (pt)
RU (1) RU2362586C2 (pt)
WO (1) WO2005037311A1 (pt)
ZA (1) ZA200603126B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23740A1 (es) * 2009-09-29 2011-12-28 Ct Ingenieria Genetica Biotech Método de obtención de una formulación de antígenos del virus de la hepatitis b
SG11202002281YA (en) 2017-10-05 2020-04-29 Toko Yakuhin Kogyo Co Ltd Nasal hepatitis b vaccine composition and method for producing same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22290A1 (es) * 1990-10-08 1995-01-31 Cigb Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunal
DE69926342T2 (de) * 1998-02-03 2006-01-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Lieferung von immunogenen molekülen unter verwendung von hbsag partikeln
CU22871A1 (es) * 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
CU23002A1 (es) * 2000-12-01 2004-11-18 Ct Ingenieria Genetica Biotech Método de obtención de agregados antigénicos y su uso en formulaciones
CU23031A1 (es) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes

Also Published As

Publication number Publication date
KR20060117920A (ko) 2006-11-17
AU2004281098A1 (en) 2005-04-28
CU23405A1 (es) 2009-08-04
CA2542680A1 (en) 2005-04-28
US20070275012A1 (en) 2007-11-29
JP2007509081A (ja) 2007-04-12
WO2005037311A1 (es) 2005-04-28
ZA200603126B (en) 2007-02-28
AR046063A1 (es) 2005-11-23
EP1676587A1 (en) 2006-07-05
RU2362586C2 (ru) 2009-07-27
AU2004281098B2 (en) 2009-06-25
RU2006117308A (ru) 2007-12-10
MXPA06004387A (es) 2006-06-14
CN1882359A (zh) 2006-12-20

Similar Documents

Publication Publication Date Title
CY1118521T1 (el) Συνθεση εμβολιου και μεθοδος χρησης αυτου
CY1106207T1 (el) Αντιιικα παραγωγα νουκλεοζιτων
MX2008013993A (es) Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular.
BRPI0518793A2 (pt) mÉtodos para tratar, controlar ou prevenir uma doenÇa ou distérbio de imunodeficiÊncia, e para melhorar a resposta imune a um imunogene, e, composiÇço farmacÊutica
BRPI0410847A (pt) dispositivo elétrico para o tratamento de lesões da pele e seus usos
IS7658A (is) Bóluefna samsetningar sem samanstanda af fitufásykrum af L2 og/eða L3 ónæmisgerð úr 1gtB mengishnettlu
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
JP2008505857A5 (pt)
BRPI0610093A2 (pt) composiÇço farmacÊutica, e, mÉtodo para prevenir ou tratar uma doenÇa associada com os depàsitos de amilàides de alfa-beta no cÉrebro de um paciente
ECSP055551A (es) Composiciones de vacunas que contienen arreglos de antígeno amiloide beta 1-6
DE60329106D1 (de) Ghrelin-träger-konjugate
SI1949913T1 (sl) Imunsko stimulacijska kombinacija za zaĺ äśito in zdravljenje hepatitisa c
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
DK1441764T3 (da) Antigen-Arrays der omfatter RANKL til behandling af knoglesygdom
AR112166A1 (es) Composiciones terapéuticas y métodos para el tratamiento de hepatitis b
ATE375804T1 (de) Ribavirin-enthaltende vakzine
DE60137146D1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
BR0207528A (pt) Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
AR054259A1 (es) Vacuna contra virus de papiloma humano (hpv)
BRPI0415654A (pt) composições farmacêuticas para uso terapêutico, uso do antìgeno de superfìcie do vìrus da hepatite b, e, método para o tratamento de infecções por vìrus de progressão crÈnica
BRPI0414026A (pt) composição para a prevenção/tratamento de infecções de hbv e doenças mediadas por hbv e método para preparar um medicamento para o tratamento terapêutico de hepatite b
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
ATE454896T1 (de) Heilkräuterzusammensetzung zur behandlung von aids
AR038311A1 (es) Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2163 DE 19/06/2012.